Technology | Contrast Media | October 04, 2016

GE Healthcare Announces FDA Labeling Change for Optison Ultrasound Contrast Agent

Administration has removed contraindication for use in patients with cardiac shunts and for administration by intra-arterial injection

GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection

October 4, 2016 — GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound contrast agent Optison (Perflutren protein-Type A Microspheres Injectable Suspension, USP). The FDA removed the contraindications for use in patients with cardiac shunts and for administration by intra-arterial injection. Both contraindications have been revised and moved to the WARNINGS AND PRECAUTIONS section (5.3 : Systemic Embolization) of the Full Prescribing Information.

Optison is the first contrast agent available in the United States to receive this contraindication label change.

A cardiac shunt is a pattern of blood flow in the heart that deviates from the normal flow of the circulatory system. Previously, in suspected cardiac shunt populations, an agitated saline procedure was needed to determine if a shunt existed and whether the patient was contraindicated to receive an ultrasound contrast agent.

Sharon L. Mulvagh, M.D., professor of medicine, Women's Heart Clinic director, associate director, preventive cardiology consultant in cardiovascular diseases, Mayo Clinic and Mayo Clinic College of Medicine, said: "I am very pleased that the FDA has approved the removal of the cardiac shunt contraindication from the ultrasound contrast agent Optison. This label change will allow more patients access to a diagnostic imaging tool that has established safety and efficacy. The FDA’s decision to remove this contraindication is supported by a body of data from studies demonstrating safety and clinical benefits of all ultrasound contrast agents in patients with cardiovascular diseases.”

She added: “This is an important step forward in eliminating barriers to ultrasound contrast use and delivering quality diagnostic care of value to our patients.”

Steven Feinstein, M.D., co-president of the International Contrast Ultrasound Society, said: “Up to one-third of our patients have known or suspected cardiac shunts and, thanks to this important FDA decision, they too will now have access to ultrasound contrast agents, which offer an inexpensive and radiation-free option for diagnostic imaging. The International Contrast Ultrasound Society applauds the FDA for its decision, and believes it will benefit individual patients as well as our healthcare delivery system.”

Jonathan Lindner, M.D., M. Lowell Edwards Professor of Cardiology at the Knight Cardiovascular Center, Oregon Health & Science University, said: “Thanks to the overwhelming weight of evidence from clinical trials, most practitioners in the field of echocardiography already realize the benefits of using contrast agents and understand their capacity to improve diagnostic accuracy, improve outcomes and streamline care. However, a major obstacle to widespread use has been lack of consensus and confusion regarding how far one needs to go to exclude shunts, no matter how small. The decision by the FDA removes a barrier to using this contrast agent, and may result in an increase in the number of labs that will choose to utilize this important technology, which allows clinicians to provide the best care possible.”

For more information: www.gehealthcare.com

Related Content

Videos | Cardiovascular Ultrasound | December 12, 2018
This is an example of the new Fetal HQ heart and vascular software from GE Healthcare for fetal ultrasound.
Hitachi Medical Systems Europe Introduces Third-Generation Intelligent Vector Flow Mapping
News | Cardiovascular Ultrasound | December 07, 2018
Hitachi Medical Systems Europe introduced what it calls the next level of intelligent Vector Flow Mapping (iVFM) at...
Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
Vygon and Sonoscanner Partnering on New Ultrasound System for Catheter Placement Guidance
News | Cardiovascular Ultrasound | October 31, 2018
Vygon, an international group specialized in single-use medical devices, and French company Sonoscanner announced the...
Hitachi Supports ASE Foundation Cardiovascular Outreach Mission in West Virginia
News | Cardiovascular Ultrasound | October 29, 2018
Hitachi Healthcare Americas participated in the cardiovascular screening and diagnostic triage event that took place...
Case Study | Cardiovascular Ultrasound | September 25, 2018
Suboptimal cardiovascular ultrasound imaging can produce transthoracic echocardiograms (TTEs) that are inconclusive,
LVivo EF Cardiac Tool Now Available for GE Vscan Extend Handheld Mobile Ultrasound
Technology | Cardiovascular Ultrasound | September 19, 2018
September 19, 2018 — DiA Imaging Analysis Ltd.
Philips Launches Epiq CVx and CVxi Cardiovascular Ultrasound Systems
Technology | Cardiovascular Ultrasound | August 22, 2018
August 22, 2018 — Philips recently announced the introduction of the Epiq CVx ...
Videos | Cardiovascular Ultrasound | July 10, 2018
DAIC Editor Dave Fornell highlights some of the most innovative new technology on the show floor of the...
Videos | Cardiovascular Ultrasound | July 03, 2018
Michael Lanspa, M.D., director of critical care echocardiography services, Intermountain Medical Center, Salt Lake Ci
Overlay Init